A Randomized, Dose-Ranging, Safety and Tolerability Study of NBI-3001 Administered by Continuous Intratumoral Infusion Followed by Surgical Resection in Patients With Recurrent Glioblastoma Multiforme

Trial Profile

A Randomized, Dose-Ranging, Safety and Tolerability Study of NBI-3001 Administered by Continuous Intratumoral Infusion Followed by Surgical Resection in Patients With Recurrent Glioblastoma Multiforme

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2013

At a glance

  • Drugs MDNA 55 (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 25 Jul 2008 Status changed from in progress to completed according to ClinicalTrials.gov.
    • 24 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top